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Abstract: The emergence of strains of the human pathogen
Candida albicans with resistance to commonly used antibiotics has
necessitated a search for new types of antifungal agents. Six
peptides with antimicrobial activity were isolated from
norepinephrine-stimulated skin secretions from the foothill
yellow-legged frog Rana boylii. Brevinin-1BYa
(FLPILASLAA10KFGPKLF CLV20TKKC) was particularly potent
against C. albicans [minimal inhibitory concentration
(MIC) ¼ 3 lM] and also active against Escherichia coli
(MIC ¼ 17 lM) and Staphylococcus aureus (MIC ¼ 2 lM), but its
therapeutic potential for systemic use is limited by its strong
hemolytic activity (HC50 ¼ 4 lM). The single amino acid
substitution (Phe12 fi Leu) in brevinin-1BYb resulted in a
fourfold lower potency against C. albicans and the additional
amino acid substitutions (Lys11 fi Thr, Phe17 fi Leu and
Val20 fi Ile) in brevinin-1BYc resulted in a ninefold decrease in
activity. Two members of the ranatuerin-2 family and one member
of the temporin family were also isolated from the secretions but
showed relatively low potency against the three microorganisms
tested.
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Introduction
Candidiasis, usually caused by Candida albicans but also
by other Candida spp. is the most common of the oppor-
tunistic fungal infections (1). Prevalence is particularly high
in a hospital environment (nosocomial infection) (2) and in
individuals with immune deficiencies such as human
immunodeficiency virus-infected patients and bone mar-
row transplant recipients (3,4). A variety of antifungal
agents (fluconazole and related azoles, amphotericin B) are
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available for treatment of Candida spp. infections but
resistance to these drugs is rapidly increasing (5,6). Conse-
quently, there is a clear need to develop new types of
antifungal agents to which the pathogens have not been
exposed in order to control infections caused by drug-
resistant strains.
The skins of frogs of the genus Rana have proved to be a
rich source of peptides with broad spectrum antibacterial
activity, some of which show antifungal properties
[reviewed in (7,8)]. The peptides are synthesized as a com-
plex array of structurally related components that may be
grouped into families on the basis of structural similarity.
Among the North American ranid frogs, nine families of
peptides have been identified: esculentin-1, esculentin-2,
brevinin-1, ranatuerin-1, ranatuerin-2, temporin, palu-
strin-1, palustrin-2, and palustrin-3 [reviewed in (9)].
Among ranid frogs of Eurasian origin, additional families
include brevinin-2 (10), tigerinin (11), japonicin-1 (12) and
japonicin-2 (12). It has been speculated that this molecular
diversity is important in protecting the animals against
invasion by a wide range of microbial species (13).
The foothill yellow-legged frog Rana boylii is a relatively
small (4–7 cm), strongly aquatic amphibian that inhabits
streams in coastal and mountain areas of California and
Oregon. Recent years have seen marked declines in popu-
lation in several regions of their range that have been
ascribed to disruptions of habitat, such as alteration of
stream flows, pollution of the environment by wind-borne
pesticides (14), and displacement by invasions of the bull-
frog, R. catesbeiana (15). It is currently being petitioned that
the species should be listed for Federal protection. The pre-
sent study describes the isolation and characterization of six
antimicrobial peptides from the skin secretions of R. boylii,
one of which shows high potency against C. albicans.
Experimental
Collection of skin secretions
A single adult male specimen of R. boylii (body weight 18 g)
was collected in Shasta County, Northern California under
California Department of Fish and Game permit number
801023-05 issued to Carlos Davidson. The animal was
transported to Vanderbilt University and housed in a poly-
carbonate vivarium containing wet and dry areas. The frog
was fed live crickets three times weekly. All experimental
procedures were approved by the Vanderbilt University
Institutional Animal Care and Use Committtee. Skin
secretions were collected at monthly intervals for 5 months
as previously described (9). In brief, the animal was injected
bilaterally with norepinephrine (2 nmol/g body wt) into the
dorsal lymph sac and placed in a solution (100 mL) of
composition 25 mm sodium chloride/25 mm ammonium
acetate, pH 7.0 for 15 min. The animal appeared to suffer no
discomfort and is still alive more than 1 year after the series
of experiments began.
The combined secretions and washings were acidified by
addition of trifluoroacetic acid (1 mL) and passed at a flow
rate of 2 mL/min through 2 Sep-Pak C-18 cartridges (Waters
Associates, Milford, MA, USA) connected in series. Bound
material was eluted with acetonitrile/water/trifluoroacetic
acid (70.0 : 29.9 : 0.1, v/v/v) and freeze-dried.
Antimicrobial and hemolytic assays
Aliquots (50 lL) of the fractions of chromatographic
effluent (Fig. 1) were tested for their ability to inhibit the
growth of Escherichia coli (ATCC 25922) and Staphylo-
coccus aureus (NCTC 8325). Lyophilized aliquots of
chromatographic effluent, reconstituted in Mueller–Hin-
ton broth (50 lL) were incubated with an inoculum (50 lL
of 5 · 105 colony forming units/mL) from an overnight
culture of the bacteria in 96-well microtiter cell-culture
plates for 18 h at 37 C in a humidified atmosphere of 5%
CO
2
in air. Incubations with C. albicans (ATCC 90028)
were carried out in RPMI 1640 medium for 48 h at 35 C.
After incubation, the absorbance at 630 nm of each well
was determined using a microtiter plate reader. Minimal
inhibitory concentrations (MICs), measured by a standard
microdilution method (16), were taken as the lowest
concentration of peptide where no visible growth was
observed. In order to monitor the validity of the assays,
incubations with E. coli and S. aureus were carried out
in parallel with increasing concentrations of the broad-
spectrum antibiotic, bacitracin and incubations with
C. albicans in parallel with amphotericin B.
Peptides in the concentration range 1–200 lm were
incubated with washed human erythrocytes (2 · 107 cells)
from a healthy donor in Dulbecco’s phosphate-buffered
saline, pH 7.4 (100 lL) for 1 h at 37 C. After centrifugation
(12 000 · g for 15 s), the absorbance at 450 nm of the
supernatant was measured. A parallel incubation in the
presence of 1% v/v Tween-20 was carried out to determine
the absorbance associated with 100% hemolysis. The HC50
value was taken as the mean concentration of peptide pro-
ducing 50% hemolysis.
Conlon et al . Antimicrobial peptides from Rana boylii
208 J. Peptide Res. 62, 2003 / 207–213
Purification of the peptides
The skin secretions, after concentration and partial purifi-
cation on Sep-Pak cartridges, were redissolved in 0.1% (v/v)
trifluoroacetic acid/water (2 mL). Secretions from months 1
to 3 were pooled together (sample A) and from months 4 and
5 were pooled together (sample B). The two samples were
separately injected onto a (25 · 1 cm) Vydac 218TP510
(C-18) reverse-phase high performance liquid chromatogra-
phy (HPLC) column (Separations Group) equilibrated with
0.1% trifluoroacetic acid/water at a flow rate of 2 mL/min.
The concentration of acetonitrile in the eluting solvent was
raised to 21% (v/v) over 10 min and 63% (v/v) over 60 min
using linear gradients. Absorbance was monitored at 214
and 280 nm and fractions (1 min) were collected. The
fractions containing antimicrobial activity were rechroma-
tographed on (25 · 1 cm) Vydac 214TP510 (C-4) column.
The concentration of acetonitrile in the eluting solvent was
raised from 35 to 63% over 40 min and the flow rate was
2 mL/min.
Structural characterization
The primary structures of the peptides were determined by
automated Edman degradation using an Applied Biosystems
(Foster City, CA, USA) procise 494 sequenator. MALDI
mass spectrometry was carried out using a Voyager RP
MALDI-TOF instrument (Perspective Biosystems Inc.,
Framingham, MA, USA) equipped with a nitrogen laser
(337 nm). The instrument was operated in reflector mode
with delayed extraction and the accelerating voltage in the
ion source was 25 kV. The instrument was calibrated with
a range of synthetic peptides and the accuracy of mass
determinations was within 0.02%.
Results
Purification of the peptides
The two pooled samples of concentrated secretions (sam-
ples A and B) were tested for their ability to inhibit growth
of the fungus C. albicans, the Gram-negative bacterium
E. coli and the Gram-positive bacterium S. aureus. Anti-
microbial activities against the three microorganisms were
detected in both crude extracts even at high sample dilu-
tion. Samples A and B were separately chromatographed on
a semi-preparative Vydac C-18 column. The elution pro-
files, shown in Fig. 1A and B, are remarkably similar par-
ticularly in the region of the chromatogram associated with
antimicrobial activity (retention times between 47 and
66 min). Five prominent, well resolved peaks, subsequently
shown to contain ranatuerin-2BYa (peak 1), brevinin-1BYa
(peak 3), brevinin-1BYb (peak 4), temporin-1BYa (peak 5),
and brevinin-1BYc (peak 6) were associated with growth-
inhibitory activity towards S. aureus. Peaks 3, 4, and 6
inhibited growth of C. albicans. Peak 2 (Fig. 1) contained a
peptide, subsequently shown to be ranatuerin-2Byb, that
inhibited the growth of E. coli only. The peptides were
purified to near homogeneity, as assessed by a symmetrical
peak shape, by further chromatography on a semiprepara-
tive Vydac C-4 column. Purification of brevinin-1BYa is
shown in Fig. 2. The final yields (nmol) of the pure peptides,
Figure 1. Reverse-phase high performance liquid chromatography on a
semipreparative Vydac C-18 column of (A) a pooled sample of Rana
boylii skin secretions collected over a 3-month period and (B) a pooled
sample collected under the same conditions over a subsequent 2-month
period. The peaks containing antimicrobial activity are designated as (1)
ranatuerin-2BYa, (2) ranatuerin-2BYb (3) brevinin-1BYa, (4) brevi-
nin-1BYb, (5) temporin-1BYa and (6) brevinin-1BYc. The dashed line
shows the concentration of acetonitrile in the eluting solvent.
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from both purifications combined, were brevinin-1BYa
(194), brevinin-1BYb (152), brevinin-1BYc (107), ranatuer-
in-2BYa (223), ranatuerin-2Byb (225), temporin-1BYa (70).
Peptide characterization
The primary structures of the antimicrobial peptides were
established by automated Edman degradation and their
amino acid sequences are shown in Fig. 3. All sequences
were obtained without ambiguity except for uncertainty
regarding the C-terminal residue of temporin-1BYa. Mass
spectrometry demonstrated that this amino acid was either
Leu amide or Ile amide but could not distinguish between
the two. However, of 30 temporin peptides that had
been characterized by the year 2000 (17), 27 terminate
in Leu.NH2 and none terminates with Ile.NH2. Mass
spectrometry demonstrated the presence of a cystine bridge
in the brevinin-1 and ranatuerin-2 peptides and the absence
of post-translational modifications to individual amino
acids (Fig. 3).
Antimicrobial and hemolytic properties
The abilities of the peptides isolated in this study to inhibit
the growth of C. albicans, E. coli and S. aureus and to produce
hemolysis of human erythrocytes are compared in Table 1.
Discussion
This article describes the purification and characterization
of six previously undescribed antimicrobial peptides from
the skin secretions of R. boylii. The primary structure of
three of the peptides identifies them as members of the
brevinin-1 family, first isolated from the skin of the Asian
frog Rana brevipoda porsa (10) and subsequently from
several species of ranid frogs of North American (9,18–23)
and European (24) origin. A comparison of the amino acid
sequences of the peptides (Fig. 3) provides insight into
structure-activity relationships within the brevinin family.
The ability of a peptide to lyse cells is the result of a
complex interelationship of factors involving conformation,
charge, hydrophobicity and amphipathicity (25). The brev-
inin-1 peptides generally comprise a N-terminal hydro-
phobic region, a proline containing hinge region in the
central portion and a C-terminal disulfide-bonded loop (26).
Circular dichroism studies have shown that the brevi-
nins adopt an amphipathic a-helical conformation in a
Figure 2. Purification of brevinin-1BYa (peak 1) on a semi-preparative
Vydac C-4 column. The arrowheads show where peak collection began
and ended.
Peptide Primary Structure Mass (a.m.u.)
Brevinin-1BYa     FLPILASLAAKFGPKLFCLVTKKC           2605.4 (26O5.6)
Brevinin-1BYb     FLPILASLAAKLGPKLFCLVTKKC           2571.5 (2571.5)
Brevinin-1BYc     FLPILASLAATLGPKLLCLITKKC           2524.5 (2524.5)
Ranatuerin-2BYa   GILSTFKGLAKGVAKDLAGNLLDKFKCKITGC   3306.8 (3306.8)
Ranatuerin-2BYb   GIMDSVKGLAKNLAGKLLDSLKCKITGC       2873.3 (2873.6)
Temporin-1BYa     FLPIIAKVLSGLL.NH2                  1381.9 (1381.9)
Figure 3. Amino acid sequences of the
antimicrobial peptides isolated from Rana
boylii skin secretions.
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membrane-mimetic environment (26). As shown in Table 1,
the substitution (Phe12 fi Leu) in brevinin-1BYa results in
a fourfold reduction in potency against C. albicans and a
twofold reduction against the gram-positive bacterium
S. aureus without significant change in potency against the
Gram-negative bacterium E. coli or in hemolytic activity.
This selective reduction in potency may be ascribed to a
decrease in hydrophobicity. In a series of analogs related to
magainin 2, it was shown that increasing overall hydro-
phobicity and hydrophobic moment (27) had relatively little
influence on activity against Gram-negative bacteria but
enhanced activity against Gram-positive bacteria (28). The
appreciably lower potency of brevinin-1BYc against micro-
organisms, particularly E. coli, may be ascribed to the sub-
stitution Lys11 fi Thr. The cationic residues in an
antimicrobial peptide are considered to be important in the
initial binding to the negatively charged phospholipids in
the cell membranes of microorganisms (25) and, up to a
certain limit, there is a good correlation between peptide
cationicity and antimicrobial potency in a range of systems
(29).
Brevinin-1BYa is the most potent peptide against
C. albicans to be isolated from frog skin by the present
investigators which, taken together with its broad spectrum
antibacterial activity, make it a candidate for drug devel-
opment. However, its therapeutic potential is seriously
limited by its strong hemolytic activity. A helical wheel
representation of brevinin-1BYa indicates that the peptide
has the propensity to form a strongly amphipathic a-helix.
Several studies have demonstrated a direct correlation
between degree of amphipathicity and hemolytic activity,
not only in peptides that form an a-helix (28,30,31), but also
those that adopt a b-sheet conformation (32). It has been
suggested that increasing the hydrophobic moment of an
antimicrobial peptide has a relatively modest effect on the
ability to permeabilize the negatively charged cell mem-
brane of microorganisms but a marked effect on the more
zwitterionic phospholipid membrane of the erythrocyte
(30). Further studies, therefore, will focus upon the syn-
thesis of brevinin-1BYa analogs with increased cationicity
but reduced amphipathicity.
Peptides of the ranatuerin-2 family were first isolated
from extracts of the skin of the bullfrog, R. catesbeiana (18)
but are widely distributed in ranid frogs of North American
origin (9,20,21,23). Consistent with properties of ranatuer-
in-2BYa and ranatuerin-2BYb, the ranatuerins generally
show low potencies against human pathogens including
C. albicans but ranatuerin-2P, isolated from the skin of
R. pipiens (20), has been shown to be active against frog
virus 3, a pathogenic iridovirus infecting anurans (33) and
three members of the family are active against Batracho-
chytrium dendrobatidis, the chytrid fungus associated with
global amphibian declines (34). Peptides of the temporin
family were first isolated from the skin of the European
frog, Rana temporaria (35) but are also widely distributed
among ranid species (17). Consistent with previous data
from the laboratory (20,21,23), temporin-1BYa selectively
inhibited the growth of S. aureus.
The reproducible reverse-phase HPLC elution profiles of
samples of R. boylii skin secretions taken at different times
several months apart (Fig. 1) illustrate the potential of this
methodology for taxonomic identification of closely-related
species or sub-populations of a particular species. Skin
secretions can be obtained from the animal under non-
invasive conditions, even from endangered species in the
wild, so that such a chromatogram provides a fingerprint
that can be used for species characterization. Combining
HPLC with mass spectrometric analysis permits unambig-
uous assignment of species. On the basis of morphological
and biochemical criteria (36,37), R. boylii is regarded as
belonging to a monophyletic group comprising R. boylii,
R. aurora, R. cascadae, R. muscosa, R. pretiosa and
Table 1. Minimal inhibitory concentrations (MICs) and hemolytic activities (HC50) of peptides isolated
from Rana boylii skin secretions
MICs (lM)
HC50 (lM)Candida albicans Escherichia coli Staphylococcus aureus
Brevinin-1BYa 3 17 2 4
Brevinin-1BYb 16 16 4 4
Brevinin-1BYc 35 NA 8 ND
Ranatuerin-2BYa NA 7 27 120
Ranatuerin-2BYb NA 17 NA >200
Temporin-1BYa NA NA 15 ND
NA, not active at 50 lM; ND, not determined.
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R. luteiventris. Although this classification has been
questioned (38), recent data involving the comparison of the
nucleotide sequences of several mitochondrial genes sup-
port monophyletic status (39). As shown in Fig. 4, the high
degree of amino acid sequence similarity between the
brevinin-1 and ranatuerin-2 peptides isolated from the skins
of R. boylii and the Columbia spotted frog R. luteiventris
(20) supports a close phylogentic relationship between the
species. However, the amino acid sequences of the tempo-
rin peptides have been much less well conserved between
the two frogs. The primary structure of temporin-1BYa
(FLPIIAKVLSGLL.NH2) resembles much more closely the
consensus sequence (FLPLIASLLSKLL.NH
2
) that has been
derived by Wade (17) from an analysis of the known temp-
orin sequences than do the primary structures of the
temporin-1La, -1Lb, and -1Lc. Assignment of these
R. luteiventris peptides to the temporin family is somewhat
arbitrary.
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Brevinin-1BYa                 FLPILASLAAKFGPKLFCLVTKKC
Brevinin-1BYb                 -----------L------------
Brevinin-1BYc                 ----------TL----L--I----
Brevinin-1La                  ---M--G---SMV---V--I----
Brevinin-1Lb                  ---M--G---SMV--FV--I----
Ranatuerin-2BYa       GILSTFKGLAKGVAKDLAGNLLDKFKCKITGC
Ranatuerin-2BYb       --MDSV-----    N---K---SL-------
Ranatuerin-2La        ---DS---V----------K----L-------
Ranatuerin-2Lb        ----SI--V------NV-AQ---TL-------
Temporin-1BYa         FLPIIA KVLSGLL.NH2
Temporin-1La          V--L-S MA-GK--.NH2
Temporin-1Lb         N--GTLINLAKK IM.NH2
Temporin-1Lc          ----LINLIHK---.NH2
Figure 4. A comparison of the primary structures
of the brevinin-1 and ranatuerin-2 peptides
isolated from Rana boylii and R. luteiventris.
()) denotes residue identity. Peptides designated
–BY are from R. boylii and designated –L are
from R. luteiventris. Gaps have been introduced
into the sequences to maximize structural
similarity.
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